Polymerase Chain Reaction Human Papillomavirus (HPV) Detection and HPV Genotyping in Invasive Cervical Cancers With Prior Negative HC2 Test Results

Tao, Xiang; Zheng, Bang; Yin, Fufen; Zeng, Zhaozhuo; Griffith, Christopher C.; Luo, Bing; Ding, Xiang; Zhou, Xianrong; Zhao, Chengquan

doi:10.1093/ajcp/aqx027

Cited by 29 publications

(26 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this study, HPV-negative tumors represented a small percentage of cervical cancer (10%). These results are in keeping with previous reports, including a previous study conducted by our group with a smaller series of cervical cancer [15,28,29,30]. sensitivity of some HPV-testing methods when applied to formalin-fixed and paraffin-embedded tissues is likely to be the cause of the high prevalence of HPV-negative tumors observed in some studies [29].…”

Section: Discussionsupporting

confidence: 91%

HPV-negative tumors of the uterine cervix

et al. 2019

View full text Add to dashboard Cite

Human papillomaviruses (HPV) are the causative agents of virtually all cervical carcinomas. Nevertheless, a small proportion of cervical cancer are negative for HPV, although the significance of this finding remains unclear. We aimed to provide insight into the differential clinico-pathological characteristics of this unusual subset of HPV-negative cervical cancer. We performed HPV-DNA detection using a highly sensitive PCR test (SPF10) and p16 immunostaining in 214 cervical carcinomas specimens from women treated at the Gynecological Oncology Unit of the Hospital Clinic (Barcelona, Spain) from 2012 to 2015. The clinical and pathological characteristics,

show abstract

Section: Discussionsupporting

confidence: 91%

HPV-negative tumors of the uterine cervix

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The hrHPV and Pap tests together enhanced the predictive power of both screening tests in a complementary fashion. As previously demonstrated by our group and others, both the hrHPV and Pap tests have considerable false‐negative rates in the detection of high‐grade cervical lesions when used alone as a screening method. The histology follow‐up data in the current study also demonstrated that neither a negative hrHPV test result nor a negative Pap test result alone brought the 3‐year cumulative risk for high‐grade cervical lesions down to a considerably safe level.…”

Section: Discussionsupporting

confidence: 60%

Age‐specific 3‐year cumulative risk of cervical cancer and high‐grade dysplasia on biopsy in 9434 women who underwent HPV cytology cotesting

Christensen

Luna³

et al. 2019

Cancer Cytopathology

View full text Add to dashboard Cite

Background High‐risk human papillomavirus (HPV)–Papanicolaou (Pap) cotesting is recommended for cervical cancer screening in women aged ≥30 years. The current study analyzed the effectiveness of cotesting on risk management in different age groups. Methods A retrospective review of a 5‐year cytology database identified 9434 women with HPV‐Pap cotesting and follow‐up cervical biopsy. The 3‐year cumulative risk of developing high‐grade cervical lesions (≥high‐grade squamous intraepithelial lesion [HSIL]) was analyzed using age stratification. Results The 3‐year cumulative risk of developing ≥HSIL was found to be significantly different in women with baseline cotesting HPV‐positive and Pap‐positive results (HPV+/Pap+; defined as ≥atypical squamous cells of undetermined significance), HPV+ and Pap‐negative results, and HPV‐negative and Pap+ results at 19.2%, 7.9%, and 3.1%, respectively (P < .001). The risk of ≥HSIL peaked at ages 30 to 39 years and significantly decreased at ages 50 to 59 years (16.6% vs 6.7%; P < .001). Women aged <30 years shared a high risk similar to that of women aged 30 to 39 years (17.3% vs 16.6%; P = .52), and risk stratification by cotesting was found to be equally effective in the younger age group (HPV+ and Pap+: 19.6%; HPV+ and Pap‐negative: 7.2%; and HPV‐negative and Pap+: 4.4% [P < .001]). Conclusions High‐risk HPV–Pap cotesting appears to be extremely sensitive for the prediction of the risk of developing ≥HSIL and is an effective tool for risk stratification. In the current study, the 3‐year cumulative risk of developing ≥HSIL varied significantly with age, with the highest risk noted among women aged <40 years and the lowest risk observed in women aged 50 to 59 years. Pap testing significantly impacted risk stratification in the HPV+ positive group, especially in women aged <60 years. Women aged <30 years were found to have a risk profile and cotesting efficacy similar to those of women aged 30 to 39 years. Modification of the current recommendation to offer cotesting to women aged ≥30 years might be considered to include those patients aged <30 years.

show abstract

“…It is important to determine whether these were negative or positive in surgical specimens. Recently, Tao et al demonstrated that humanpapillomavirus DNA was detectable in 44.3% of prior negative invasive cervical cancers (based on Hybrid Capture 2; Qiagen, Gaithersburg, Maryland, USA), using surgical specimens for polymerase chain reaction testing 14. In this study, humanpapillomavirus DNA was positive in 40.0% of pretreatment DNA genotype negative cervical cancer cases.…”

Section: Discussionmentioning

confidence: 49%

“…Moreover, a recent study found that 8–19% of cases were humanpapillomavirus negative, with an average of 14%, using cytology specimens 14. Our previous study also showed that the high risk human papillomavirus negative rate was 18.5% in pretreatment DNA genotype testing 6.…”

Section: Discussionmentioning

confidence: 67%

Prevalence, survival outcomes, and clinicopathologic factors associated with negative high risk human papillomavirus in surgical specimens of cervical cancer with pretreatment negative DNA genotype test

Chong

Han

Park

et al. 2019

Int J Gynecol Cancer

View full text Add to dashboard Cite

ObjectiveThe aim of this study was to detect high risk human papillomavirus in cervical cancer with a pretreatment negative high risk human papillomavirus DNA genotype test and to evaluate clinicopathologic characteristics and survival outcomes according to high risk human papillomavirus status.MethodsWe investigated high risk human papillomavirus status in surgical specimens from 30 cases of cervical cancer using polymerase chain reaction. Polymerase chain reaction primers were set to detect the presence of the common L1 and E7 regions of human papillomavirus types 16, 18, 31, 33, 45, 52, and 58. We analyzed the following clinicopathologic parameters to evaluate their relationships with high risk human papillomavirus status: age, histology, stage, tumor size, invasion depth, lymphovascular invasion, and recurrent status.ResultsAmong 30 cases with a pretreatment negative DNA genotype test, high risk human papillomavirus was detected in 12 (40.0%), whereas 18 (60.0%) were negatives. Of 12 high risk human papillomavirus positive cases, 10 (33.3%) were positive for the L1 region, 6 (20.0%) of the 7 types were positive for the E7 region, and 4 (13.1%) were positive for both L1 and E7 regions. According to a multiple logistic regression model, tumor size (odds ratio 7.80; 95% confidence interval 1.476 to 41.216; P=0.0097) and stage (odds ratio 7.00; 95% confidence interval 1.293 to 37.910; P=0.0173) were associated with negative high risk human papillomavirus DNA status. Kaplan–Meier survival plots showed that negative high risk human papillomavirus status was associated with worse disease free survival in contrast with positive high risk human papillomavirus status (P=0.0392).ConclusionsNegative high risk human papillomavirus was found in 60% of cervical cancers with a pretreatment negative DNA genotype test. Moreover, the negative high risk human papillomavirus group was associated with worse survival outcome.

show abstract

Polymerase Chain Reaction Human Papillomavirus (HPV) Detection and HPV Genotyping in Invasive Cervical Cancers With Prior Negative HC2 Test Results

Cited by 29 publications

References 20 publications

HPV-negative tumors of the uterine cervix

HPV-negative tumors of the uterine cervix

Age‐specific 3‐year cumulative risk of cervical cancer and high‐grade dysplasia on biopsy in 9434 women who underwent HPV cytology cotesting

Prevalence, survival outcomes, and clinicopathologic factors associated with negative high risk human papillomavirus in surgical specimens of cervical cancer with pretreatment negative DNA genotype test

Contact Info

Product

Resources

About